Study of brain cooling and clot-busting drug therapy for stroke receives FDA OK to expand

February 6, 2013

An international multicenter clinical trial led by a Cedars-Sinai neurologist on the combination of brain cooling and "clot-busting" drug therapy after stroke has received Food and Drug Administration approval to expand from 50 patients to 400.

"This approval is highly significant because, after reviewing our initial safety data, the approved us to include more patients in our study," said Patrick D. Lyden, MD, chair of the Department of Neurology at Cedars-Sinai Medical Center and the study's overall principal investigator. Thomas Hemmen, MD, PhD, director of the University of California, San Diego Health System Stroke Center, and James C. Grotta, MD, chair of the Department of Neurology at the University of Texas Health Science Center at Houston (UTHealth), are co-.

This study, which includes the use of intravenous (IV tPA), the only FDA-approved treatment for acute stroke, is the latest in a series of clinical trials on brain cooling – controlled hypothermia – to reduce neurological damage after stroke.

Researchers employ a state-of-the-art system to provide rapid heat exchange and very fast cooling, achieved by inserting a special catheter into the inferior vena cava – the body's largest vein. No fluid enters the patient; an internal circulation within the catheter absorbs the body's heat and transfers it out to slow metabolism, keep tissue swelling in check and give the brain time to rest.

Study participants are covered with a warming blanket to trick the body into feeling warm, and temperature sensors in the skin and a mild sedative help suppress shivering. Body temperature is cooled to 33 degrees Celsius (about 91 degrees Fahrenheit) for 24 hours before the patient is gradually warmed.

Brain cooling has been shown to decrease brain swelling and reduce loss of neurological function after . It also has proved highly effective in saving lives and preventing neurological damage after heart attack and after oxygen deprivation in newborns.

TPA, which must be given to a patient as quickly as possible after onset, sometimes can dissolve a clot and prevent or reduce serious brain injury. Lyden, the Carmen and Louis Warschaw Chair in Neurology at Cedars-Sinai, helped lead the pivotal clinical trial of the drug that led to its approval by the FDA in 1996.

Explore further: Hypothermia protects the brain against damage during stroke

Related Stories

Hypothermia protects the brain against damage during stroke

March 6, 2012

Thromboembolic stroke, caused by a blood clot in the brain, results in damage to the parts of the brain starved of oxygen. Breaking up the clot with tissue plasminogen activator (tPA) reduces the amount of damage, however, ...

Recommended for you

Scientists track unexpected mechanisms of memory

September 29, 2016

Do you remember Simone Biles's epic gymnastics floor routine that earned her a fifth Olympic medal? Our brains hold on to memories like these via physical changes in synapses, the tiny connections between neurons.

Some brains are blind to moving objects

September 28, 2016

As many as half of people are blind to motion in some part of their field of vision, but the deficit doesn't have anything to do with the eyes.

Oligodendrocytes induce motor neuron death in ALS

September 27, 2016

A first-of-its-kind oligodendrocyte in vitro model shows that human cells normally supportive of motor neuron function play an active role in amyotrophic lateral sclerosis pathogenesis – and this discovery may point the ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.